Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Methods for administration of taxol|
|Abstract:||Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/m.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following pretreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.|
|Inventor(s):||Canetta; Renzo Mauro (Madison, CT), Eisenhauer; Elizabeth (Kingston, CA), Rozencweig; Marcel (Bradford, CT)|
|Assignee:||Bristol-Myers Squibb Company (Princeton, NJ)|
|Filing Date:||Nov 22, 1996|
|Claims:||1. A method for reducing peripheral neurotoxicity symptoms in patients suffering from lung cancer and undergoing taxol therapy comprising reducing peripheral neurotoxicity symptoms in said patients while maintaining an anti-tumor effect by administering about 135 mg/m.sup.2 taxol over a period of about 24 hours. |
2. The method of claim 1 wherein the administration of taxol is repeated at least once, about 21 days after the preceding administration.
3. A method for reducing peripheral neurotoxicity symptoms in patients suffering from colon cancer and undergoing taxol therapy comprising reducing peripheral neurotoxicity symptoms in said patients while maintaining an anti-tumor effect by administering about 135 mg/m.sup.2 taxol over a period of about 24 hours.
4. The method of claim 3 wherein the administration of taxol is repeated at least once, about 21 days after the preceding administration.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.